Data has shown a correlation between the severity of lower urinary tract symptoms (LUTS) and the severity of erectile dysfunction (ED).
Researchers from the United States explored the question of whether LUTS severity can impact a patient?s response to ED treatment.
Researchers used data from a randomized, double-blind, placebo-controlled study examining the safety and efficacy of tadalafil in men with moderate to severe benign prostatic hyperplasia (BPH) to perform this post-hoc analysis.
Of the 281 men enrolled in the study, 156 (68 percent) had a medical history of ED. Patients participated in a four-week, single-blind placebo run before being randomized to receive 5 mg tadalafil daily for six week with an increase to 20 mg daily for an additional six weeks. The control arm received placebo for the 12-week period. Patients were evaluated using the International Index of Erectile Function — Erectile Function (IIEF EF). Scores were significantly improved in patients receiving tadalafil as opposed to placebo, though no statistically significant difference was seen between patients with moderate BPH vs. severe BPH.